share_log

HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $12

HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $12

HC Wainwright & Co.維持對Allogene Therapeutics的買入,將目標價下調至12美元
Benzinga ·  2023/11/15 07:38

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $23 to $12.

HC Wainwright & Co. 分析師羅伯特·伯恩斯維持Allogene Therapeutics(納斯達克股票代碼:ALLO)的買入,並將目標股價從23美元下調至12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論